We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Foghorn Therapeutics Inc. (FHTX - Free Report) shares ended the last trading session 13.1% higher at $6.65. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3% gain over the past four weeks.
This surge is most likely attributable to the recovery of the share price after it dived earlier this week when FHTX announced pausing enrollment in its phase I study on FHD-609 for the treatment of synovial sarcoma and SMARCB1-deleted tumors after complications in a synovial sarcoma patient at the second highest dose. The FDA placed the study on partial clinical hold after the company notified the authorities.
This company is expected to post quarterly loss of $0.68 per share in its upcoming report, which represents a year-over-year change of -4.6%. Revenues are expected to be $6.09 million, up 55.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Foghorn Therapeutics Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FHTX going forward to see if this recent jump can turn into more strength down the road.
Foghorn Therapeutics Inc. is part of the Zacks Medical - Drugs industry. Aclaris Therapeutics (ACRS - Free Report) , another stock in the same industry, closed the last trading session 0.7% lower at $8.89. ACRS has returned 11.3% in the past month.
Aclaris' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.44. Compared to the company's year-ago EPS, this represents a change of -41.9%. Aclaris currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
Foghorn Therapeutics Inc. (FHTX - Free Report) shares ended the last trading session 13.1% higher at $6.65. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3% gain over the past four weeks.
This surge is most likely attributable to the recovery of the share price after it dived earlier this week when FHTX announced pausing enrollment in its phase I study on FHD-609 for the treatment of synovial sarcoma and SMARCB1-deleted tumors after complications in a synovial sarcoma patient at the second highest dose. The FDA placed the study on partial clinical hold after the company notified the authorities.
This company is expected to post quarterly loss of $0.68 per share in its upcoming report, which represents a year-over-year change of -4.6%. Revenues are expected to be $6.09 million, up 55.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Foghorn Therapeutics Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FHTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Foghorn Therapeutics Inc. is part of the Zacks Medical - Drugs industry. Aclaris Therapeutics (ACRS - Free Report) , another stock in the same industry, closed the last trading session 0.7% lower at $8.89. ACRS has returned 11.3% in the past month.
Aclaris' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.44. Compared to the company's year-ago EPS, this represents a change of -41.9%. Aclaris currently boasts a Zacks Rank of #3 (Hold).